Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study

نویسندگان

  • Hasu Eun
  • Hoon Hur
  • Cheul Soo Byun
  • Sang-Yong Son
  • Sang-Uk Han
  • Yong Kwan Cho
چکیده

PURPOSE Although several clinical trials have proven the efficacy of adjuvant S-1 treatment in gastric cancers, it is still unclear which patients receive the most benefit. In this study, we prospectively recruited patients with locally advanced gastric cancer who had undergone curative resection followed by adjuvant S-1 administration to investigate which factors affect the outcomes. MATERIALS AND METHODS Between July 2010 and October 2011, we enrolled 49 patients who underwent curative resection for stage II or III gastric cancer and who subsequently received adjuvant S-1 treatment for 1 year. RESULTS Twenty-nine patients (59.2%) continued S-1 treatment for 1 year, and 12 patients (24.5%) experienced recurrent disease during the follow-up period. Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1. Multivariate analysis indicated poor outcomes for patients with stage III disease and those who discontinued S-1 treatment. Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020). CONCLUSIONS S-1 is tolerated as adjuvant treatment in gastric cancer patients. However, discontinuing S-1 treatment may be an unfavorable factor in the prevention of recurrence. S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Survival in Nonmetastatic Gastric Cancer Patients

Background & Aims: Gastric carcinoma is the second most frequent cancer worldwide. Adjuvant treatment of gastric cancer varies worldwide; many differences have been observed in their clinical and pathological features, and survival rate. The aim of this study was to determine clinical and pathological features, and survival rate in a group of patients in south-east of Iran. Methods: Patient rec...

متن کامل

Comparison of the incidence and severity of side effects profile of FOLFOX and DCF regimens in gastric cancer patients

Abstract Introduction: Gastric cancer is the fourth common cancer and the second leading cause of cancer death worldwide. Due to lack of adequate information on the side effects of chemotherapy regimens in treatment of gastric cancer, this study was aimed to determine the side effects of two common chemotherapy regimens of gastric cancer. Methods: This prospective study was conducte...

متن کامل

Comparison of the incidence and severity of side effects profile of FOLFOX and DCF regimens in gastric cancer patients

Abstract Introduction: Gastric cancer is the fourth common cancer and the second leading cause of cancer death worldwide. Due to lack of adequate information on the side effects of chemotherapy regimens in treatment of gastric cancer, this study was aimed to determine the side effects of two common chemotherapy regimens of gastric cancer. Methods: This prospective study was conducte...

متن کامل

Estimating the Net Survival of Patients with Gastric Cancer in Iran in a Relative Survival Framework

Background: Iran is an Eastern Mediterranean region country with the highest rate of gastric cancer. The present study aimed to evaluate the 5-year net survival of patients with gastric cancer in Iran using a relative survival framework.Methods: In a cross-sectional study, using life-table estimation of relative survival, we reported 1- to 5-year relative survival regarding age, sex, disease st...

متن کامل

Effects of Melatonin on IL-6 Serum Level Changes and Fatigue Caused by Adjuvant Chemoradiotherapy in Breast Cancer Women: A Randomized Controlled Trial

Introduction: Cancer-related fatigue is one of the most common and debilitating complications of breast cancer. Cancer patients have been found to have lower levels of melatonin, and fatigue has been shown to be correlated with both melatonin and interleukin (IL-6) in cancer patients. This study aimed to evaluate the fatigue and serum level of IL-6 in response to melatonin treatment in breast c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2015